Travoprost extended release - Envisia Therapeutics

Drug Profile

Travoprost extended release - Envisia Therapeutics

Alternative Names: ENV-515

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Liquidia Technologies
  • Developer Envisia Therapeutics
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma

Most Recent Events

  • 03 Feb 2017 Updated efficacy data from a phase II trial in Glaucoma released by Envisia Therapeutics
  • 17 Oct 2016 Updated efficacy and adverse events data from a phase II trial in Glaucoma released by Envisia Therapeutics
  • 06 Oct 2015 Efficacy and adverse events data from a phase IIa trial in Glaucoma released by Envisia Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top